ERBB2 and gastric cancer: On the basis of KEYNOTE-859, the FDA approved pembrolizumab with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative GC or GEJC [8,9].